JP2009545310A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009545310A5 JP2009545310A5 JP2009522416A JP2009522416A JP2009545310A5 JP 2009545310 A5 JP2009545310 A5 JP 2009545310A5 JP 2009522416 A JP2009522416 A JP 2009522416A JP 2009522416 A JP2009522416 A JP 2009522416A JP 2009545310 A5 JP2009545310 A5 JP 2009545310A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid construct
- disorders
- acid sequence
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 206010021143 Hypoxia Diseases 0.000 claims 4
- 230000007954 hypoxia Effects 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 108091062157 Cis-regulatory element Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000005538 encapsulation Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000010412 perfusion Effects 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 210000003038 endothelium Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 108091027981 Response element Proteins 0.000 claims 1
- 208000016599 Uterine disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000010478 bone regeneration Effects 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 claims 1
- 229920000831 ionic polymer Polymers 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 208000015670 renal artery disease Diseases 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83415706P | 2006-07-31 | 2006-07-31 | |
| US60/834,157 | 2006-07-31 | ||
| PCT/IL2007/000959 WO2008015675A2 (en) | 2006-07-31 | 2007-07-31 | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014000121A Division JP2014121326A (ja) | 2006-07-31 | 2014-01-06 | ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009545310A JP2009545310A (ja) | 2009-12-24 |
| JP2009545310A5 true JP2009545310A5 (OSRAM) | 2010-08-05 |
| JP5513885B2 JP5513885B2 (ja) | 2014-06-04 |
Family
ID=38997565
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522416A Expired - Fee Related JP5513885B2 (ja) | 2006-07-31 | 2007-07-31 | ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用 |
| JP2014000121A Pending JP2014121326A (ja) | 2006-07-31 | 2014-01-06 | ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014000121A Pending JP2014121326A (ja) | 2006-07-31 | 2014-01-06 | ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20100298226A1 (OSRAM) |
| EP (1) | EP2051988A4 (OSRAM) |
| JP (2) | JP5513885B2 (OSRAM) |
| KR (1) | KR20090038921A (OSRAM) |
| CN (2) | CN102796741A (OSRAM) |
| AU (1) | AU2007280017B2 (OSRAM) |
| CA (1) | CA2658972C (OSRAM) |
| MX (1) | MX2009001157A (OSRAM) |
| NZ (1) | NZ574410A (OSRAM) |
| WO (1) | WO2008015675A2 (OSRAM) |
| ZA (1) | ZA200900581B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| CA2463816C (en) | 2001-10-19 | 2014-07-08 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| CN102796741A (zh) | 2006-07-31 | 2012-11-28 | 脉管生物生长有限公司 | 多肽和其编码多核苷酸及它们在治疗缺血相关医学病症中的应用 |
| KR20110036101A (ko) * | 2008-06-30 | 2011-04-06 | 안지오블라스트 시스템스 인코퍼레이티드 | 조합된 치료를 사용한 안과질환 및 과도한 혈관신생의 치료 |
| KR101810257B1 (ko) | 2010-01-05 | 2017-12-18 | 바스큘라 바이오제닉스 리미티드 | 아교모세포종 ｇｂｍ을 치료하기 위한 조성물 및 방법 |
| NZ601324A (en) | 2010-01-05 | 2014-10-31 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| SG182490A1 (en) | 2010-01-12 | 2012-08-30 | Vascular Biogenics Ltd | Methods of producing adenovirus vectors and viral preparations generated thereby |
| WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
| NZ707336A (en) | 2012-10-17 | 2019-01-25 | Vascular Biogenics Ltd | Treatment methods using adenovirus |
| WO2014118643A2 (en) | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| CA2898122A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| CN107602682A (zh) * | 2016-07-07 | 2018-01-19 | 胡国田 | 一种多肽及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1073420A (zh) * | 1991-12-18 | 1993-06-23 | 济南火柴厂 | 一种无硫无铬火柴的制造方法 |
| US6124131A (en) | 1998-08-25 | 2000-09-26 | The Johns Hopkins University School Of Medicine | Mutant hypoxia inducible factor-1 HIF-1 |
| WO2002012326A2 (en) * | 2000-08-07 | 2002-02-14 | Angiogenetics Sweden Ab | Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
| ATE455562T1 (de) * | 2000-11-17 | 2010-02-15 | Vascular Biogenics Ltd | Endothelzellspezifität zeigende promotoren und verfahren zu deren verwendung |
| US7067649B2 (en) | 2000-11-17 | 2006-06-27 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US6849718B2 (en) * | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US7193053B2 (en) * | 2003-04-25 | 2007-03-20 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hypoxia-inducible factor 1alpha variants and methods of use |
| CN102796741A (zh) | 2006-07-31 | 2012-11-28 | 脉管生物生长有限公司 | 多肽和其编码多核苷酸及它们在治疗缺血相关医学病症中的应用 |
| KR101810257B1 (ko) | 2010-01-05 | 2017-12-18 | 바스큘라 바이오제닉스 리미티드 | 아교모세포종 ｇｂｍ을 치료하기 위한 조성물 및 방법 |
| NZ601324A (en) | 2010-01-05 | 2014-10-31 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| SG182490A1 (en) | 2010-01-12 | 2012-08-30 | Vascular Biogenics Ltd | Methods of producing adenovirus vectors and viral preparations generated thereby |
| WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
-
2007
- 2007-07-31 CN CN2012102106463A patent/CN102796741A/zh active Pending
- 2007-07-31 NZ NZ574410A patent/NZ574410A/en not_active IP Right Cessation
- 2007-07-31 WO PCT/IL2007/000959 patent/WO2008015675A2/en not_active Ceased
- 2007-07-31 MX MX2009001157A patent/MX2009001157A/es active IP Right Grant
- 2007-07-31 US US12/309,856 patent/US20100298226A1/en not_active Abandoned
- 2007-07-31 AU AU2007280017A patent/AU2007280017B2/en not_active Ceased
- 2007-07-31 EP EP07790014A patent/EP2051988A4/en not_active Withdrawn
- 2007-07-31 KR KR20097004288A patent/KR20090038921A/ko not_active Withdrawn
- 2007-07-31 CA CA2658972A patent/CA2658972C/en active Active
- 2007-07-31 CN CN2007800358630A patent/CN101516902B/zh not_active Expired - Fee Related
- 2007-07-31 JP JP2009522416A patent/JP5513885B2/ja not_active Expired - Fee Related
-
2009
- 2009-01-26 ZA ZA200900581A patent/ZA200900581B/xx unknown
-
2011
- 2011-06-20 US US13/163,776 patent/US20110319479A1/en not_active Abandoned
-
2014
- 2014-01-06 JP JP2014000121A patent/JP2014121326A/ja active Pending
- 2014-09-24 US US14/495,614 patent/US9403887B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | A collagen hydrogel loaded with HDAC7-derived peptide promotes the regeneration of infarcted myocardium with functional improvement in a rodent model | |
| JP2010155842A5 (OSRAM) | ||
| AU2013335684B2 (en) | Novel method for treating cardiac infarction using HMGB1 fragment | |
| JP2026041749A5 (OSRAM) | ||
| JP7405345B2 (ja) | 間葉系幹細胞の動員活性を有するペプチド | |
| CN102178984B (zh) | 用于治疗心肌梗死的海藻酸钠-蛋白胶可注射凝胶材料的制备方法 | |
| RU2010135532A (ru) | Лечение и предупреждение болезней сердца с использованием двух или более изоформ фактора роста гепатоцидов | |
| JP2012105650A5 (OSRAM) | ||
| RU2013127565A (ru) | Ингибиторы апоптоза и их применение | |
| RU2009128647A (ru) | Варианты дезинтегрина и их фармацевтическое применение | |
| CN114432332A (zh) | circUTRN在制备治疗心力衰竭药物中的应用、重组载体和治疗心力衰竭的药物 | |
| BR112015008745B1 (pt) | Uso de um peptídeo de fragmento de hmgb1 para a fabricação de um medicamento para o tratamento de lesão do cordão espinhal | |
| JP2020172505A5 (OSRAM) | ||
| JP2019521976A5 (OSRAM) | ||
| Fidelis-de-Oliveira et al. | Soluble factors from multipotent mesenchymal stromal cells have antinecrotic effect on cardiomyocytes in vitro and improve cardiac function in infarcted rat hearts | |
| JP2023513847A5 (OSRAM) | ||
| Yang et al. | Inhibition of neuron and cardiac remodeling by microenvironment-responsive injectable hydrogels with sympatho-immune regulation properties for myocardial infarction therapy | |
| CN104862281A (zh) | 表达bFGF和PDGF-BB的重组载体修饰的间充质干细胞及其制备方法和用途 | |
| ES2338529T3 (es) | Prometores que exiben especificidad por celulas endoteliales y metodos para su utilizacion. | |
| JPWO2021020509A5 (OSRAM) | ||
| CN113980144B (zh) | 一种多肽类似物及其应用 | |
| CN101991573A (zh) | 去氢钩藤碱及其异构体在制备药物中的用途 | |
| CN103243091B (zh) | miRNA-140抑制剂及其用途 | |
| JP2014512369A5 (OSRAM) | ||
| CN111184743A (zh) | 多类型混合细胞在心肌梗死细胞治疗中的应用 |